Psoriatic arthritis PDF
Preview Psoriatic arthritis
O R L OXFORD RHEUMATOLOGY LIBRARY Psoriatic Arthritis O R L OXFORD RHEUMATOLOGY LIBRARY Psoriatic Arthritis Dafna D. Gladman , MD, FRCPC Senior Scientist, Toronto Western Research Institute. Centre for prognosis studies in the rheumatic diseases, Toronto Western Hospital, Toronto, Canada; Department of Medicine, Division of Rheumatology, University of Toronto, Canada Cheryl F. Rosen , MD, FRCPC Head, Division of Dermatology, Toronto Western Hospital Professor, Department of Medicine, University of Toronto, Toronto, Canada Vinod Chandran , MBBS, MD, DM, PhD Centre for prognosis studies in the rheumatic diseases, Toronto Western Hospital, Toronto, Canada; Department of Medicine, Division of Rheumatology, University of Toronto, Canada 3 3 Great Clarendon Street, Oxford, OX2 6DP, United Kingdom Oxford University Press is a department of the University of Oxford. It furthers the University’s objective of excellence in research, scholarship, and education by publishing worldwide. Oxford is a registered trade mark of Oxford University Press in the UK and in certain other countries © Oxford University Press 2014 The moral rights of the authors have been asserted Impression: 1 All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, without the prior permission in writing of Oxford University Press, or as expressly permitted by law, by licence or under terms agreed with the appropriate reprographics rights organization. Enquiries concerning reproduction outside the scope of the above should be sent to the Rights Department, Oxford University Press, at the address above You must not circulate this work in any other form and you must impose this same condition on any acquirer Published in the United States of America by Oxford University Press 198 Madison Avenue, New York, NY 10016, United States of America British Library Cataloguing in Publication Data Data available Library of Congress Control Number: 2013957509 ISBN 978–0–19–969209–5 Printed in Great Britain by Ashford Colour Press Ltd, Gosport, Hampshire Oxford University Press makes no representation, express or implied, that the drug dosages in this book are correct. Readers must therefore always check the product information and clinical procedures with the most up-to-date published product information and data sheets provided by the manufacturers and the most recent codes of conduct and safety regulations. The authors and the publishers do not accept responsibility or legal liability for any errors in the text or for the misuse or misapplication of material in this work. Except where otherwise stated, drug dosages and recommendations are for the non-pregnant adult who is not breastfeeding. Links to third party websites are provided by Oxford in good faith and for information only. Oxford disclaims any responsibility for the materials contained in any third party website referenced in this work. Contents Symbols and Abbreviations vii 1 Epidemiology 1 2 Diagnostic and classifi cation criteria 5 3 Aetiology and pathogenesis 13 4 Clinical and laboratory features of musculoskeletal manifestations 17 5 Skin and nail disease 27 6 Imaging in psoriatic arthritis 35 7 Making a diagnosis of psoriatic arthritis 51 8 Assessment of disease activity and damage in psoriatic arthritis 57 v 9 Therapeutics 69 10 Surgery 77 11 Co-morbidities 81 12 Team approach to the management of psoriatic arthritis 85 13 Prognosis 87 14 The future 93 Index 95 Symbols and Abbreviations ACR American College of Rheumatology ADEPT Adalimumab Eff ectiveness in Psoriatic Arthritis Trial Apo apolipoprotein AS ankylosing spondylitis ASA acetylsalicylic acid ASAS Assessment of SpondyloArthritis International Society AxPsA axial psoriatic arthritis BASDAI Bath Ankylosing Spondylitis Disease Activity Index BASRI Bath Ankylosing Spondylitis Radiology Index BSA Body Surface Area method of quantitating psoriasis CASPAR ClASsifi cation criteria for Psoriatic ARthritis CCP cyclic citrullinated peptide vii CI confi dence interval CXCL1 growth-regulated protein α precursor; GRO- α CPDAI Composite Psoriatic Disease Activity Index CRP C-reactive protein DAPSA Disease Activity Index for Psoriatic Arthritis DAS Disease Activity Score DIP distal interphalangeal DLQI Dermatology Life Quality Index DMARDs disease modifying anti-rheumatic drugs EA enteropathic arthritis ESSG European Spondyloarthropathy Study Group ESR erythrocyte sedimentation rate EULAR European League Against Rheumatism GHS General Health Status GRACE Group for Research and Assessment of Psoriasis and Psoriatic Arthritis Composite Exercise GRAPPA Group for Research and Assessment of Psoriasis and Psoriatic Arthritis GRO- α growth-regulated protein α precursor; CXCL1 GUESS Glasgow Ultrasound Enthesitis Scoring System HADS Hospital Anxiety and Depression Scale S HAQ Health Assessment Questionnaire N O HIV human immunodefi ciency virus TI VIA HLA human leukocyte antigen E R HPA hypothalamic-pituitary-adrenal B B A IBD infl ammatory bowel disease D N ICAM-1 intercellular adhesion molecule 1 A S ICC intraclass correlation coeffi cient L O B IL interleukin M Y IMPACT Infl iximab Multinational Psoriatic Arthritis Controlled Trials S IMT carotid intima-media wall thickness JNT joint JSN joint space narrowing KIR killer-cell immunoglobulin-like receptor LDI Leeds Dactylitis Index LS-PGA Lattice System Physician Global Assessment M-CSF monocyte colony stimulating factor viii MASES Maastricht Ankylosing Spondylitis Enthesitis Score MCP metacarpophalangeal MCP1/CCL2 monocyte chemotactic protein 1 MDA Minimal Disease Activity MDGDA physician global assessment MHC major histocompatibility complex MRI magnetic resonance imaging MTP metatarsophalangeal MTX methotrexate mSASSS modifi ed Stokes Ankylosing Spondylitis Spinal Score mTSS modifi ed total Sharp score NAFLD non-alcoholic fatty liver disease NAPSI Nail Psoriasis Severity Index NK natural killer cells NPF National Psoriasis Foundation NPF-PS National Psoriasis Foundation Psoriasis Score NSAIDs non-steroidal anti-infl ammatory drugs OA osteoarthritis OMERACT Outcome Measures in Rheumatology PAQ Psoriatic Arthritis Questionnaire PARS Psoriatic Arthritis Ratingen Score PASE Psoriatic Arthritis Screening Evaluation S N PASI Psoriasis Area and Severity Index O TI PASRI Psoriatic Arthritis Spondylitis Radiology Index VIA E PCA principal component analysis R B B PGA Physician Global Assessment A D PGA-Ps psoriasis disease activity N A PIP proximal interphalangeal S L O PsA psoriatic arthritis B M PsAJAI The Psoriatic Arthritis Joint Activity Index Y S PsAMRIS Psoriatic Arthritis Magnetic Resonance Imaging Scoring PsAQoL Psoriatic Arthritis Quality of Life PsARC PsA Response Criteria PtGA patient global assessment PTGDA patient global disease assessment PUVA psoralen and ultraviolet A radiation RA rheumatoid arthritis RAI Ritchie Articular Index ix RANKL receptor activator of nuclear factor κB ligand RANTES Regulated on Activation, Normal T-cell Expressed and Secreted RASSS Radiographic AS Spinal Score RCT randomized controlled trial ReA reactive arthritis RNF ring fi nger protein SAPHO Synovitis, Acne, Pustulosis, Hyperostosis, and Osteitis SCORE Systematic Coronary Risk Evaluation SD standard deviation SF-36 Short Form-36 Health Survey SJC Swollen Joint Count SMR standardized mortality ratio SNP single nucleotide polymorphism SpA spondyloarthritis SPARCC Spondyloarthritis Research Consortium of Canada SPR standardized prevalence ratio SSZ sulfasalazine TNF tumor necrosis factor TNFAIP3 TNF- α induced protein 3 TRAF3 TNF receptor-associated factor 3
Description:The list of books you might like
